Journal article

Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?

Vilija G Jokubaitis, Yuan Zhou, Helmut Butzkueven, Bruce V Taylor

Current Treatment Options in Neurology | CURRENT MEDICINE GROUP | Published : 2018

Abstract

PURPOSE OF REVIEW: This review will examine the current evidence that genetic and/or epigenetic variation may influence the multiple sclerosis (MS) clinical course, phenotype, and measures of MS severity including disability progression and relapse rate. RECENT FINDINGS: There is little evidence that MS clinical phenotype is under significant genetic control. There is increasing evidence that there may be genetic determinants of the rate of disability progression. However, studies that can analyse disability progression and take into account all the confounding variables such as treatment, clinical characteristics, and environmental factors are by necessity longitudinal, relatively small, an..

View full abstract

Grants

Funding Acknowledgements

Helmut Butzkueven is on the Australian advisory board and Global Advisory boards for Novartis, Biogen, Merck, and Teva, and is a consultant for Novartis (Progressive MS consultancy) and Oxford Pharmagenesis (MS Brain Health Steering Committee). Dr. Butzkueven reports research grants from Biogen and Novartis and lecture fees paid to him from Biogen. Dr. Butzkueven has received payment for the development of educational presentations for Biogen (MS Atlas Meetings), Novartis (National MS workshop), and Merck (Global Registries workshop).